Clinical trials: psoriasis
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Psoriasis
Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis
This is a proof of concept, investigator blinded study to evaluate the efficacy and safety of a novel combination of a home narrow band ultraviolet B (NBUVB) lamp with an occlusive dressing in adult subjects with mild to moderate…
- Trial name
- NCT02447068
- Testing
- Luma Light System, Luma Light, Occlusive Dressing
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Illumicure Inc
Psoriasis
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT05096364
- Where
- 13 sites in China
- Volunteers
- 251 people
- Sponsor
- Akeso
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients
This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose…
- Trial name
- NCT02555709
- Testing
- VTP-43742
- Where
- 14 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Plaque Psoriasis
An Open-Label Study to Assess Safety
An Open-Label study to assess safety
- Trial name
- NCT03645499
- Testing
- Topical TA-102 A, Topical TA-102 B, Topical TA-102 C
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Rheumatoid Arthritis, Ankylosing Spondylitis
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- NCT05866614
- Testing
- Remsima IV, Remsima SC
- Where
- France
- Volunteers
- 881 people
- Sponsor
- Celltrion
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis.
- Trial name
- NCT06176508
- Testing
- HS-10374, Tofacitinib 5Mg Tab,Oral
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Hansoh BioMedical R&D Company
Plaque Psoriasis
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis.
- Trial name
- NCT07733089
- Testing
- ZP9830
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Zealand Pharma
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Psoriasis, Arthritis, Psoriatic
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
The main objective of this study is to compare the relative bioavailability, safety, and tolerability of extended-release and immediate-release apremilast formulations in healthy participants.
- Conditions
- Psoriasis, Arthritis, Psoriatic, Oral Ulcer
- Trial name
- NCT07908641
- Testing
- Apremilast XR, Apremilast IR
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Amgen
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Chronic Plaque Psoriasis
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a Phase 3 Study to Compare Pharmacokinetics, Efficacy and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT05495568
- Testing
- CT-P17, EU-approved Humira
- Where
- Estonia
- Volunteers
- 367 people
- Sponsor
- Celltrion
Psoriasis
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
Study is not recruiting and using secondary data sources only
- Trial name
- NCT04799990
- Testing
- Risankizumab, Comparator 1, Comparator 2
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had…
- Trial name
- NCT04908189
- Testing
- Deucravacitinib, Apremilast
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 729 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis, Psoriasis
Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis
Pruritis is a common symptom in patients with atopic dermatitis and psoriasis. Patients with atopic dermatitis and psoriasis often report pruritis-associated sleep impairments and scratching behaviors during nighttime and the…
- Trial name
- DECODE-Scratch (NCT06448689)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- ActiGraph L.L.C
Psoriasis
MAP Study: Methotrexate and Adalimumab in Psoriasis
Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.
- Trial name
- MAP (NCT03217734)
- Testing
- Adalimumab, Methotrexate
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jeffrey J Crowley MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.